UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

The New England journal of medicine, 2015-04, Vol.372 (16), p.1489-1499

2015

Volltextzugriff (PDF)

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2015-01, Vol.385 (9965), p.331-340

2015

Volltextzugriff (PDF)

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Atherosclerosis, 2016-11, Vol.254, p.254-262

2016

Volltextzugriff (PDF)

Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)

Journal of the American College of Cardiology, 2014-04, Vol.63 (13), p.1278-1288

2014

Volltextzugriff (PDF)

Is prediabetes a cardiovascular risk factor in patients with coronary artery disease?

European journal of preventive cardiology, 2023-10, Vol.30 (14), p.1416-1417

Langslet, Gisle

2023

Volltextzugriff (PDF)

Dairy fat and cardiovascular disease: good or bad? A lipidologist's view

European journal of preventive cardiology, 2023-02, Vol.30 (3), p.217-218

Langslet, Gisle

2023

Volltextzugriff (PDF)

Efficacy and Safety of Pitavastatin in Children and Adolescents at High Future Cardiovascular Risk

The Journal of pediatrics, 2015-08, Vol.167 (2), p.338-343.e5

2015

Volltextzugriff (PDF)

Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study

The Lancet (British edition), 2015-05, Vol.385 (9983), p.2153-2161

2015

Volltextzugriff (PDF)

LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia

Journal of clinical lipidology, 2019-03, Vol.13 (2), p.279-286

2019

Volltextzugriff (PDF)

Efficacy and Safety of Rosuvastatin Therapy for Children With Familial Hypercholesterolemia

Journal of the American College of Cardiology, 2010-03, Vol.55 (11), p.1121-1126

2010

Volltextzugriff (PDF)

A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia

Journal of clinical lipidology, 2016-09, Vol.10 (5), p.1153-1162.e3

2016

Volltextzugriff (PDF)

Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study

Cardiovascular drugs and therapy, 2020-08, Vol.34 (4), p.515-523

2020

Volltextzugriff (PDF)

Replacing statins with PCSK9-inhibitors and delaying treatment until 18 years of age in patients with familial hypercholesterolaemia is not a good idea

European heart journal, 2016-05, Vol.37 (17), p.1357-1359

Langslet, Gisle

2016

Volltextzugriff (PDF)

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia

Journal of clinical lipidology, 2017-01, Vol.11 (1), p.195-203.e4

2017

Volltextzugriff (PDF)

Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study

The lancet. Diabetes & endocrinology, 2014-06, Vol.2 (6), p.455-463

2014

Volltextzugriff (PDF)

Lipoprotein(a) in children and adolescents with genetically confirmed familial hypercholesterolemia followed up at a specialized lipid clinic

Atherosclerosis plus, 2024-09, Vol.57, p.13-18

2024

Volltextzugriff (PDF)

Risk of Recurrent Coronary Events in Patients With Familial Hypercholesterolemia; A 10-Years Prospective Study

Frontiers in pharmacology, 2021-03, Vol.11, p.560958-560958

2021

Volltextzugriff (PDF)

Young women with familial hypercholesterolemia have higher LDL-cholesterol burden than men: Novel data using repeated measurements during 12-years follow-up

Atherosclerosis plus, 2023-03, Vol.51, p.28-34

2023

Volltextzugriff (PDF)

Thirty percent of children and young adults with familial hypercholesterolemia treated with statins have adherence issues

American journal of preventive cardiology, 2021-06, Vol.6, p.100180-100180, Article 100180

2021

Volltextzugriff (PDF)

Apheresis in homozygous familial hypercholesterolemia: The results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia

Journal of clinical lipidology, 2012-07, Vol.6 (4), p.331-339

2012

Volltextzugriff (PDF)

Long-term follow-up of young adults with familial hypercholesterolemia after participation in clinical trials during childhood

Journal of clinical lipidology, 2015-11, Vol.9 (6), p.778-785

2015

Volltextzugriff (PDF)

Durability of Alirocumab Effect: Data From an Open-Label Extension to the ODYSSEY Program for Patients With Heterozygous Familial Hypercholesterolemia

Journal of clinical lipidology, 2017-05, Vol.11 (3), p.840-840

2017

Volltextzugriff (PDF)

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

European heart journal, 2015-11, Vol.36 (43), p.2996-3003

2015

Volltextzugriff (PDF)

Screening methods in the diagnosis and assessment of children and adolescents with familial hypercholesterolemia

Expert review of cardiovascular therapy, 2013-08, Vol.11 (8), p.1061-1066

2013

Volltextzugriff (PDF)

1 – 25 von 103

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(99)
Mit Volltextzugriff
(96)

Publikationsform

Artikel
(103)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(60)
Science & Technology
(60)
Humans
(41)
Cardiovascular System & Cardiology
(32)
Cardiac & Cardiovascular Systems
(29)
Female
(29)
Male
(29)
Cardiovascular
(28)
Cholesterol, Ldl - Blood
(20)
Middle Aged
(20)
Pharmacology & Pharmacy
(20)
Familial Hypercholesterolemia
(19)
Treatment Outcome
(19)
Hyperlipoproteinemia Type Ii - Drug Therapy
(18)
Cardiology
(17)
Internal Medicine
(17)
Double-Blind Method
(16)
Low Density Lipoprotein
(15)
Cholesterol
(14)
Adolescent
(13)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)

Is prediabetes a cardiovascular risk factor in patients with coronary artery disease?

Dairy fat and cardiovascular disease: good or bad? A lipidologist's view

Efficacy and Safety of Pitavastatin in Children and Adolescents at High Future Cardiovascular Risk

Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study

LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia

Efficacy and Safety of Rosuvastatin Therapy for Children With Familial Hypercholesterolemia

A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia

Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study

Replacing statins with PCSK9-inhibitors and delaying treatment until 18 years of age in patients with familial hypercholesterolaemia is not a good idea

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia

Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study

Lipoprotein(a) in children and adolescents with genetically confirmed familial hypercholesterolemia followed up at a specialized lipid clinic

Risk of Recurrent Coronary Events in Patients With Familial Hypercholesterolemia; A 10-Years Prospective Study

Young women with familial hypercholesterolemia have higher LDL-cholesterol burden than men: Novel data using repeated measurements during 12-years follow-up

Thirty percent of children and young adults with familial hypercholesterolemia treated with statins have adherence issues

Apheresis in homozygous familial hypercholesterolemia: The results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia

Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study

Long-term follow-up of young adults with familial hypercholesterolemia after participation in clinical trials during childhood

Durability of Alirocumab Effect: Data From an Open-Label Extension to the ODYSSEY Program for Patients With Heterozygous Familial Hypercholesterolemia

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

Screening methods in the diagnosis and assessment of children and adolescents with familial hypercholesterolemia

Suchergebnisse filtern